Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
The week tilts toward a few companies making room to move. Two big capital raises landed on the same day, and a couple of diagnostic and sequencing shops are quietly reshaping what their tools can do. None of it is flashy, but the thread runs through the same part of the business: the companies that need cash to scale, and the ones that are trying to make their core technology reach further.
Assembly Biosciences closed a follow-on offering, raising approximately $115 million, with plans to put the money toward clinical development. Editas Medicine priced a public offering at $2.25 per share and warrant, expecting about $125 million in gross proceeds, with the potential to reach $319 million if all warrants are exercised. Both moves point to companies in gene therapy and precision medicine needing room to run their trials and scale manufacturing. Nanobiotix also closed a global offering with full exercise of the underwriters' option, signaling continued appetite for capital in oncology-focused biotech. For the firms that run these trials and handle the harder manufacturing work, this tends to mean busier months ahead.
Myriad Genetics launched Prolaris + AI, a prostate cancer test that pairs genomic data with digital pathology artificial intelligence, meaning software that reads tissue slides automatically. PacBio began shipping SPRQ-Nx chemistry worldwide, enabling full genome sequences at under $300 each using AI-enhanced sequencing, with new reusable sequencing cells that cut costs by 30 percent. Both moves lean the same way: making precision diagnostics and genomics cheaper and faster to run. For companies that sell into diagnostics, research tools, or market access, the angle is that lower costs tend to open up new use cases and larger patient populations. We only see what we happen to pick up, so treat this as a few signals, not the whole board.
The FDA also approved a handful of new drugs and generics through the week, including two new molecular entities from Shionogi and Haisco, a new formulation from Flex Pharma, and generic versions of oxcarbazepine and epinephrine. Routine work, but steady.